By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genomic Health said today that it has accelerated development of its prostate cancer test with the goal of launching it in 2013, a year earlier than it had previously estimated.

The firm also said that Israeli insurance firm Clalit has agreed to provide reimbursement for its Oncotype Dx colon cancer test and that it expects to report results from a second recurrence study in stage II colon cancer in 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.